Short answer · Medically reviewed summary · Last updated: 2026-04-07
Turner Syndrome was first clinically described by Dr. Henry Turner in 1938, though the underlying chromosomal cause—the complete or partial absence of one X chromosome—was not identified until 1959.
1 people with Turner Syndrome have shared their first-person experience on this question at DiseaseMaps.
What is the history of Turner Syndrome?
History of Turner Syndrome: when and how it was discovered, and the milestones in research since, medically reviewed.
Turner Syndrome was first clinically described by Dr. Henry Turner in 1938, though the underlying chromosomal cause—the complete or partial absence of one X chromosome—was not identified until 1959. Today, our understanding of Turner Syndrome has shifted from a focus on static physical traits to a comprehensive, multidisciplinary approach that emphasizes early hormonal intervention and lifelong health monitoring.
When was Turner Syndrome first identified?
While reports of individuals with features consistent with the condition appeared in medical literature as early as the 19th century, the formal clinical description of Turner Syndrome is credited to Dr. Henry Turner. In 1938, he presented a case study of seven women who shared a distinct set of characteristics, including short stature, webbed necks, and a lack of secondary sexual development. At that time, Dr. Turner recognized the constellation of symptoms but did not yet understand the genetic origin of Turner Syndrome.
How did our understanding of the cause evolve?
The true nature of Turner Syndrome remained a mystery for over two decades until the dawn of modern cytogenetics. In 1959, Dr. Charles Ford and his colleagues discovered that the condition was caused by a missing X chromosome (45,X karyotype). This breakthrough transformed Turner Syndrome from a vaguely defined endocrine disorder into a recognized chromosomal condition. We now know that Turner Syndrome affects approximately 1 in 2,500 live female births, and it is not typically inherited, but rather results from a random error during cell division in early development.
What are the major milestones in treatment and advocacy?
The medical management of Turner Syndrome has seen significant advancements that have drastically improved quality of life. Key historical milestones include:
- 1940s-50s: Initial use of estrogen therapy to help induce secondary sexual characteristics.
- 1980s: The introduction of recombinant human growth hormone (rhGH) therapy, which revolutionized the ability to improve final adult height in those with Turner Syndrome.
- 1990s-Present: The establishment of standardized clinical guidelines, moving away from fragmented care toward a "medical home" model involving cardiologists, endocrinologists, and psychologists.
- Community Growth: Advocacy organizations have emerged to provide support, with 414 people with Turner Syndrome currently sharing their experiences and insights on the DiseaseMaps.org community platform.
How have historical misconceptions been corrected?
Historically, patients with Turner Syndrome were often stigmatized or misdiagnosed due to limited knowledge regarding their fertility and cognitive abilities. Early literature often incorrectly portrayed the condition as being associated with intellectual disability. Modern research has corrected this; while some individuals may face specific learning challenges—particularly in non-verbal areas like spatial visualization or executive function—most people with Turner Syndrome have normal intelligence. Furthermore, the focus has shifted from "curing" the condition to empowering patients through early detection and personalized medical management.
Next steps
- Consult an endocrinologist specializing in Turner Syndrome to ensure your care plan aligns with current clinical guidelines.
- Join a patient support group or the DiseaseMaps.org community to connect with others who understand the lived experience of this condition.
- Schedule regular screenings for cardiovascular and renal health, as these are critical components of long-term care for adults and children with the diagnosis.
Medical disclaimer: This content is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Turner Syndrome Overview
- Orphanet: Turner Syndrome (ORPHA:881)
- Online Mendelian Inheritance in Man (OMIM): 45,X; Turner Syndrome (#300087)
- Turner Syndrome Society of the United States: Clinical Guidelines
À l'époque, la description était purement clinique, car on ne déterminait pas encore les caryotypes. Les premiers caryotypes datent de 1959. L'année suivante, Charles E. Ford décrivait l'existence de la monosomie X, c’est-à-dire l'absence d'un chromosome X, qui caractérise les syndromes de Turner les plus fréquents.
En 1965, les anomalies de l'X ont été décrites pour la première fois. Les premiers traitements de la petite taille du syndrome de Turner par l'hormone de croissance, datent des années 1990 (1986, autorisation de mise sur le marché sous protocole).
Posted Jul 24, 2019 by Association "Turner et vous"
